Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on June 2, 2023, covering events occurring on June 1, 2023. The registrant is a Delaware corporation headquartered in Farmington Hills, Michigan, and is classified as an Emerging Growth Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance amendments and does not contain financial performance data.
Material Changes
On June 1, 2023, the Board of Directors approved a Third Amendment to the Company's Second Amended and Restated Bylaws. The material change involves reducing the quorum requirement for all stockholder meetings from a majority of the voting power of outstanding shares to one-third of the voting power of outstanding shares entitled to vote. This amendment became effective immediately.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report, other than the standard reference to the full text of the Bylaws Amendment filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the exact text of the Third Amendment to the Bylaws in Exhibit 3.1 to confirm the new quorum threshold.
- Confirm the impact of the reduced quorum requirement on future stockholder meeting outcomes and corporate governance stability.
- Review recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial data.